Cariprazine
- Generic Name
- Cariprazine
- Brand Names
- Vraylar, Reagila
- Drug Type
- Small Molecule
- Chemical Formula
- C21H32Cl2N4O
- CAS Number
- 839712-12-8
- Unique Ingredient Identifier
- F6RJL8B278
- Background
Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT receptors and as an antagonist at serotonin 5-HT receptors. Cariprazine has been investigated in a variety of psychiatric disorders, including schizophrenia, bipo...
- Indication
Cariprazine is indicated for the treatment of schizophrenia in adults to manage both positive and negative symptoms. It is also indicated to monotherapy for acute management of manic or mixed episodes associated with bipolar I disorder (bipolar mania) in adults, and acute management of depressive episodes associated with bipolar I disorder (bipolar depressio...
- Associated Conditions
- Bipolar Disorder With Manic or Mixed Episodes, Depressive Episodes, Schizophrenia
- Associated Therapies
- -
Sequential Multiple Assignment Randomized Trial for Bipolar Depression
- Conditions
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 2726
- Registration Number
- NCT06433635
- Locations
- 🇺🇸
McLean Hospital, Belmont, Massachusetts, United States
🇺🇸John Hopkins, Baltimore, Maryland, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
Effectiveness of Cariprazine Monotherapy for Treatment of Major Depressive Disorder
- Conditions
- Interventions
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- Sultan Qaboos University
- Target Recruit Count
- 110
- Registration Number
- NCT05933538
Lithium Versus Cariprazine in the Acute Phase Treatment of Bipolar Depression (DUAG9)
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Aalborg University Hospital
- Target Recruit Count
- 122
- Registration Number
- NCT05913947
- Locations
- 🇩🇰
Aalborg University Hospital, Aalborg, Denmark
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 161
- Registration Number
- NCT05439616
- Locations
- 🇺🇸
Cincinnati Children's Hospital /ID# 243968, Cincinnati, Ohio, United States
🇺🇸Core Clinical Research /ID# 243084, Everett, Washington, United States
🇺🇸Family Psychiatry of The Woodlands /ID# 242867, The Woodlands, Texas, United States
Cariprazine Versus Placebo for Social Anxiety Disorder
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- The Medical Research Network
- Target Recruit Count
- 40
- Registration Number
- NCT05384483
- Locations
- 🇺🇸
The Medical Research Network, LLC, New York, New York, United States
Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With Schizophrenia
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 34
- Registration Number
- NCT05368558
- Locations
- 🇯🇵
Hayakawa Clinic /ID# 242432, Kure City, Hiroshima, Japan
🇯🇵National Hospital Organization Kure Medical Center /ID# 243405, Kure-shi, Hiroshima, Japan
🇯🇵Hokkaido University Hospital /ID# 243245, Sapporo-shi, Hokkaido, Japan
Dopamine D3 Receptor Occupancy in Bipolar Depression
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 8
- Registration Number
- NCT05060549
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Adjunct Treatment With Cariprazine for Adults With Attention-deficit/Hyperactivity Disorder
- First Posted Date
- 2021-04-13
- Last Posted Date
- 2021-12-14
- Lead Sponsor
- Dr. Martin A. Katzman
- Target Recruit Count
- 15
- Registration Number
- NCT04843423
- Locations
- 🇨🇦
START Clinic for Mood and Anxiety Disorders, Toronto, Ontario, Canada
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
- First Posted Date
- 2021-03-02
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 380
- Registration Number
- NCT04777357
- Locations
- 🇺🇸
Beaumont Psychiatric Clinic /ID# 267484, Beaumont, Texas, United States
🇺🇸Pillar Clinical Research /ID# 226504, Bentonville, Arkansas, United States
🇺🇸Advanced Research Center /ID# 227073, Anaheim, California, United States
Assessing the Role of Cariprazine in Improving Cognition in Euthymic Bipolar Patients
- Conditions
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Lakshmi N Yatham
- Target Recruit Count
- 1
- Registration Number
- NCT04771299
- Locations
- 🇨🇦
Djavad Mowfaghian Centre for Brain Heath, Vancouver, British Columbia, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.